Aptose Biosciences (NASDAQ:APTO – Get Free Report) and VectivBio (NASDAQ:VECT – Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.
Valuation and Earnings
This table compares Aptose Biosciences and VectivBio’s gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Aptose Biosciences | N/A | N/A | -$51.21 million | ($6.20) | -0.12 |
VectivBio | $27.34 million | N/A | -$93.74 million | N/A | N/A |
Aptose Biosciences has higher earnings, but lower revenue than VectivBio.
Institutional & Insider Ownership
Analyst Ratings
This is a summary of recent recommendations and price targets for Aptose Biosciences and VectivBio, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Aptose Biosciences | 0 | 0 | 6 | 0 | 3.00 |
VectivBio | 0 | 0 | 0 | 0 | N/A |
Aptose Biosciences currently has a consensus price target of $14.83, indicating a potential upside of 1,875.93%. Given Aptose Biosciences’ higher possible upside, equities research analysts plainly believe Aptose Biosciences is more favorable than VectivBio.
Profitability
This table compares Aptose Biosciences and VectivBio’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Aptose Biosciences | N/A | -1,003.74% | -257.64% |
VectivBio | N/A | N/A | N/A |
About Aptose Biosciences
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
About VectivBio
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.